2021
DOI: 10.1007/s40200-021-00855-7
|View full text |Cite
|
Sign up to set email alerts
|

A randomized double-blind placebo controlled pilot study of probiotics in adolescents with severe obesity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
10
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(10 citation statements)
references
References 47 publications
0
10
0
Order By: Relevance
“…The randomized allocation of participants was mentioned in all included trials. However, only five trials described randomized sequence generation methods ( 16 , 17 , 19 , 21 , 23 ), and six trials reported allocation concealment ( 16 , 17 , 19 , 21 23 ). With the exception of Ipar’s study ( 20 ), which used an open-label design, the remaining seven studies had a low risk of blinding bias among participants, researchers, and outcome assessors.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…The randomized allocation of participants was mentioned in all included trials. However, only five trials described randomized sequence generation methods ( 16 , 17 , 19 , 21 , 23 ), and six trials reported allocation concealment ( 16 , 17 , 19 , 21 23 ). With the exception of Ipar’s study ( 20 ), which used an open-label design, the remaining seven studies had a low risk of blinding bias among participants, researchers, and outcome assessors.…”
Section: Resultsmentioning
confidence: 99%
“…The effect of probiotics on weight was analyzed by five studies ( 16 , 17 , 20 , 21 , 23 ), 132 in the experimental group and 120 in the control group. The meta-merge heterogeneity was significant ( I 2 = 68%, P =0.01), and the random effect model was applied to merge, as shown in Figure 3A .…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“… 26 The ESPEN guidelines recommended using Vivomixx® in patients with mild to moderate ulcerative colitis (UC), confirming its efficacy in protecting the gut barrier and normalizing gut flora. 27 Vivomixx® was found to decrease the gut microbial Firmicutes to Bacteroidetes (F/B) ratio (representing dysbiosis markers) in obese adolescents 28 as well as in mice. 29 In CF patients, decreased levels of Bacteroidetes and Firmicutes were found compared to healthy controls, while reduced microbial richness correlated with intestinal inflammation.…”
Section: Discussionmentioning
confidence: 99%
“…No significant change in the fasting insulin, HOMA-IR, or serum and stool inflammatory markers were noted between the two groups. One participant in the treatment arm reported adverse effects of gastrointestinal intolerance [ 160 ].…”
Section: Nutritional Strategies For Modulation Of Insulin Resistancementioning
confidence: 99%